Phase II study of weekly paclitaxel following fixed three cycles of S-1-based chemotherapy for advanced gastric cancer

Hepato-Gastroenterology

Volumn 58, Issue 106, 2011, Pages 652-658

  Ohashi, Manabu ^a,e   Kanda, Tatsuo ^a   Kobayashi, Takashi ^b   Hirota, Masaki ^c   Hayami, Morihito ^d   Yajima, Kazuhito ^a   Matsuki, Atsushi ^a   Kosugi, Shin Ichi ^a   Hatakeyama, Katsuyoshi ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b Niigata Rinko Hospital   (Japan)

^c Niigata Prefectural Muikamachi Hospital   (Japan)

^d Niigata Minami Hospital   (Japan)

^e TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

Gastric cancer; S 1; Second line chemotherapy; Sequential set chemotherapy; Weekly paclitaxel

Indexed keywords

CIMETIDINE; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; PACLITAXEL; TS 1; UNCLASSIFIED DRUG;

ADULT; AGED; ALLERGY; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DERMATITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG SAFETY; FEMALE; GASTRECTOMY; HUMAN; LEUKOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY DYSFUNCTION; STOMACH ADENOCARCINOMA; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VALIDITY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OXONIC ACID; PACLITAXEL; STOMACH NEOPLASMS; TEGAFUR;

EID: 79958175162     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Murad AM, Santiago FE, Petroianu A, Rocha PR, Rodrigues MA, Rausch M: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72:37-41. (Pubitemid 23182046)
2. Glimelius B, Hoffman K, Haglund U, Nyrén O, Sjödén PO: Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 1994; 5:189-190. (Pubitemid 24062577)
3. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M: Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71:587-591.
4. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998; 34:1715-1720. (Pubitemid 28474225)
5. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, Shirao K, Matsumura Y, Gotoh M: Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003; 89:2207-2212.
6. Stathopoulos G.P, Rigatos SK, Fountzilas G, Polyzos A, Stathopoulos JG: Paclitaxel and carboplatin in pre-treated advanced gastric cancer: a phase II study. Oncology Reports 2002; 9:89-92.
7. Kanat O, Evrensel T, Manavoglu O, Demiray M, Kurt E, Gonullu G, Kiyici M, Arslan M: Single-agent irrinotecan as second-line treatment for advanced gastric cancer. Tumori 2003; 89:405-407. (Pubitemid 37279923)
8. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamanmoto S, Fukuda H, Yoshida S: Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003; 21:54-59.
9. Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF: Phase II study of taxol in patients with advanced gastric carcinoma Cancer. J Sci Am 1998; 4:269-274.
10. Rowinsky EK, Donehower RC, Jones RJ, Tucker RW: Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 1998; 48:4093-4100.
11. Fennelly DW, Aghajanim C, Shapiro F, O'Flaherty C, McKenzie M, O'Connor C, Tong W, Norton L, Spriggs D: Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997; 15:187-192. (Pubitemid 27020572)
12. Seidman AD, Hudis CA, Albanell J, Tong W, Tepler I, Currie V, Moynahan ME, Theodoulou M, Gollub M, Baselga J, Norton L: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998; 16:3353-3361. (Pubitemid 28481632)
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van OOsterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors, European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
14. Japanese Gastric Cancer Association: Japanese classification of gastric carcinoma, 2nd English edition. Gastric Cancer 1998; 1:10-24.
15. Kaplan EN and Meier P: Non parametric estimation from incomplete observations. J Am Asat Assoc 1958; 53:457-481.
16. Kodera Y, Ito S, Mochizuki Y, Fujitake S, Koshikawa K, Kanyama Y, Matsui T, Kojima H, Takase T, Ohashi N, Fujiwara M, Sakamoto J, Nakao A: A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG302 study). Anticancer Res 2007; 27:2667-2672.
17. Hironaka S, Zenda S, Boku N, Fukutomi A, Yoshino T, Onozawa Y: Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer 2006; 9:14-18.
18. Assersohn L, Brown G, Cunningham D, Ward C, Oates J, Waters JS, Hill ME, Norman AR: Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol 2004; 15:64-69. (Pubitemid 38145530)
19. Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, Todo S, Terashima M, Gotoh M, Sakamoto J, Nishiyama M: Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 2006; 12:3402-3407.
20. Inokuchi M, Yamashita T, Yamada T, Kojima K, Ichikawa W, Nihei Z, Kawano T, Sugihara K: Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer. Br J Cancer 2006; 94:1130-1135.
21. Mochiki E, Ohno T, Kamiyama Y, Aihara R, Haga N, Ojima H, Nakamura J, Ohsawa H, Nakabayashi T, Takeuchi K, Asao T, Kuwano H: Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer. Br J Cancer 2006; 95:1642-1647. (Pubitemid 44950789)
22. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 2006; 24:4991-4997. (Pubitemid 46631401)
23. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358:36-46.
24. Catalano V, Graziano F, Santini D, D'Emidio S, Baldelli AM, Rossi D, Vincenzi B, Giordani P, Alessandroni P, Testa E, Tonini G, Catalano G: Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? Br J Cancer 2008; 99:1402-1407.
25. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9:215-221.